Literature DB >> 24189064

Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling.

Xuewei Wu1, Jun Qi, James E Bradner, Gutian Xiao, Lin-Feng Chen.   

Abstract

The etiology of human T cell leukemia virus 1 (HTLV-1)-mediated adult T cell leukemia is associated with the ability of viral oncoprotein Tax to induce sustained NF-κB activation and the expression of many NF-κB target genes. Acetylation of the RelA subunit of NF-κB and the subsequent recruitment of bromodomain-containing factor Brd4 are important for the expression of NF-κB target genes in response to various stimuli. However, their contributions to Tax-mediated NF-κB target gene expression and tumorigenesis remain unclear. Here we report that Tax induced the acetylation of lysine 310 of RelA and the binding of Brd4 to acetylated RelA to facilitate Tax-mediated transcriptional activation of NF-κB. Depletion of Brd4 down-regulated Tax-mediated NF-κB target gene expression and cell proliferation. Inhibiting the interaction of Brd4 and acetylated RelA with the bromodomain extraterminal protein inhibitor JQ1 suppressed the proliferation of Tax-expressing rat fibroblasts and Tax-positive HTLV-1-infected cells and Tax-mediated cell transformation and tumorigenesis. Moreover, JQ1 attenuated the Tax-mediated transcriptional activation of NF-κB, triggering the polyubiquitination and proteasome-mediated degradation of constitutively active nuclear RelA. Our results identify Brd4 as a key regulator for Tax-mediated NF-κB gene expression and suggest that targeting epigenetic regulators such as Brd4 with the bromodomain extraterminal protein inhibitor might be a potential therapeutic strategy for cancers and other diseases associated with HTLV-1 infection.

Entities:  

Keywords:  Acetylation; Brd4; Cancer; HTLV-1; JQ1; Leukemia; NF-κB; Signaling; TAX; Transcription

Mesh:

Substances:

Year:  2013        PMID: 24189064      PMCID: PMC3861657          DOI: 10.1074/jbc.M113.485029

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

Review 1.  Dynamic roles for NF-κB in HTLV-I and HIV-1 retroviral pathogenesis.

Authors:  Jonathan K Chan; Warner C Greene
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

Review 2.  Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

Authors:  Subash C Gupta; Chitra Sundaram; Simone Reuter; Bharat B Aggarwal
Journal:  Biochim Biophys Acta       Date:  2010-05-21

Review 3.  Activation of NF-kappaB by HTLV-I and implications for cell transformation.

Authors:  Shao-Cong Sun; Shoji Yamaoka
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

Review 4.  Modulation of nuclear factor-kappaB by human T cell leukemia virus type 1 Tax protein: implications for oncogenesis and inflammation.

Authors:  Jean-Marie Peloponese; Man Lung Yeung; Kuan-Teh Jeang
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 5.  HIV-1, HTLV-1 and normal T-cell growth: transcriptional strategies and surprises.

Authors:  W C Greene; E Böhnlein; D W Ballard
Journal:  Immunol Today       Date:  1989-08

6.  Gallic acid suppresses lipopolysaccharide-induced nuclear factor-kappaB signaling by preventing RelA acetylation in A549 lung cancer cells.

Authors:  Kyung-Chul Choi; Yoo-Hyun Lee; Myung Gu Jung; Seung Hyun Kwon; Mi-Jeong Kim; Woo Jin Jun; Jeongmin Lee; Jae Myun Lee; Ho-Geun Yoon
Journal:  Mol Cancer Res       Date:  2009-12-08       Impact factor: 5.852

Review 7.  The IL-2/IL-15 receptor systems: targets for immunotherapy.

Authors:  Thomas A Waldmann
Journal:  J Clin Immunol       Date:  2002-03       Impact factor: 8.317

8.  Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain.

Authors:  Lele Zhao; Danyan Cao; Tiantian Chen; Yingqing Wang; Zehong Miao; Yechun Xu; Wuyan Chen; Xin Wang; Yanlian Li; Zhiyan Du; Bing Xiong; Jian Li; Chunyan Xu; Naixia Zhang; Jianhua He; Jingkang Shen
Journal:  J Med Chem       Date:  2013-05-14       Impact factor: 7.446

9.  Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA.

Authors:  Z Zou; B Huang; X Wu; H Zhang; J Qi; J Bradner; S Nair; L-F Chen
Journal:  Oncogene       Date:  2013-05-20       Impact factor: 9.867

Review 10.  HTLV-1 and apoptosis: role in cellular transformation and recent advances in therapeutic approaches.

Authors:  John M Taylor; Christophe Nicot
Journal:  Apoptosis       Date:  2008-06       Impact factor: 4.677

View more
  22 in total

1.  Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage.

Authors:  Beatriz Suarez-Alvarez; José Luis Morgado-Pascual; Sandra Rayego-Mateos; Ramon M Rodriguez; Raul Rodrigues-Diez; Pablo Cannata-Ortiz; Ana B Sanz; Jesus Egido; Pierre-Louis Tharaux; Alberto Ortiz; Carlos Lopez-Larrea; Marta Ruiz-Ortega
Journal:  J Am Soc Nephrol       Date:  2016-07-19       Impact factor: 10.121

Review 2.  The bromodomain: from epigenome reader to druggable target.

Authors:  Roberto Sanchez; Jamel Meslamani; Ming-Ming Zhou
Journal:  Biochim Biophys Acta       Date:  2014-03-28

3.  BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy.

Authors:  Andrew Antolic; Hiroko Wakimoto; Zhe Jiao; Joshua M Gorham; Steven R DePalma; Madeleine E Lemieux; David A Conner; Da Young Lee; Jun Qi; Jonathan G Seidman; James E Bradner; Jonathan D Brown; Saptarsi M Haldar; Christine E Seidman; Michael A Burke
Journal:  JCI Insight       Date:  2020-08-06

Review 4.  Molecular biology of human T cell leukemia virus.

Authors:  Lee Ratner
Journal:  Semin Diagn Pathol       Date:  2019-04-16       Impact factor: 3.464

5.  The suppression of bromodomain and extra-terminal domain inhibits vascular inflammation by blocking NF-κB and MAPK activation.

Authors:  Mingcheng Huang; Shan Zeng; Yaoyao Zou; Maohua Shi; Qian Qiu; Youjun Xiao; Guoqiang Chen; Xiuyan Yang; Liuqin Liang; Hanshi Xu
Journal:  Br J Pharmacol       Date:  2016-11-18       Impact factor: 8.739

6.  Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma.

Authors:  Masao Nakagawa; Arthur L Shaffer; Michele Ceribelli; Meili Zhang; George Wright; Da Wei Huang; Wenming Xiao; John Powell; Michael N Petrus; Yibin Yang; James D Phelan; Holger Kohlhammer; Sigrid P Dubois; Hee Min Yoo; Emmanuel Bachy; Daniel E Webster; Yandan Yang; Weihong Xu; Xin Yu; Hong Zhao; Bonita R Bryant; Joji Shimono; Takashi Ishio; Michiyuki Maeda; Patrick L Green; Thomas A Waldmann; Louis M Staudt
Journal:  Cancer Cell       Date:  2018-07-26       Impact factor: 31.743

7.  Methods to detect NF-κB acetylation and methylation.

Authors:  JinJing Chen; Lin-Feng Chen
Journal:  Methods Mol Biol       Date:  2015

8.  Pre-clinical analysis of changes in intra-cellular biochemistry of glioblastoma multiforme (GBM) cells due to c-Myc silencing.

Authors:  Vishal Rajagopalan; Muthukumar Vaidyanathan; Vanisree Arambakkam Janardhanam; James E Bradner
Journal:  Cell Mol Neurobiol       Date:  2014-07-24       Impact factor: 5.046

Review 9.  Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.

Authors:  Lei-lei Fu; Mao Tian; Xiang Li; Jing-jing Li; Jian Huang; Liang Ouyang; Yonghui Zhang; Bo Liu
Journal:  Oncotarget       Date:  2015-03-20

10.  Induction of Cell Death in Growing Human T-Cells and Cell Survival in Resting Cells in Response to the Human T-Cell Leukemia Virus Type 1 Tax.

Authors:  Mariko Mizuguchi; Yuka Sasaki; Toshifumi Hara; Masaya Higuchi; Yuetsu Tanaka; Noriko Funato; Nobuyuki Tanaka; Masahiro Fujii; Masataka Nakamura
Journal:  PLoS One       Date:  2016-02-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.